{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.135","meta":{"versionId":"6","lastUpdated":"2021-03-06T01:00:16.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135","version":"20210306","name":"Dolasetron Oral","status":"active","date":"2021-03-06T01:00:16-05:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"310006","display":"dolasetron 100 MG Oral Tablet"},{"code":"310007","display":"dolasetron 50 MG Oral Tablet"}]}]},"expansion":{"identifier":"urn:uuid:73355503-800a-4c34-942d-373a44923f4e","timestamp":"2022-06-10T07:10:56-04:00","total":2,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"310006","display":"dolasetron 100 MG Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"310007","display":"dolasetron 50 MG Oral Tablet"}]}}